Provectus Biopharmaceuticals Inc (PVCT)

[vorlon1966]

No it is not. The trial design was well thought out. The writers point on sample size was it was half of some. But those "other drug sample sizes" were half of others.

The sample size depends on what the efficacy is.
The better the drug works the less of a sample you need... provided it is safe.
But if you have a drug that only works a bit better than the comparator you have to have a much larger sample size to make sure your data is not random fluctuations. The writer kindly overlooked that or is just ignorant on statistics.

There is plenty of money to reach the midpoint.
They will need more to go past mid point.

The writer is not a doctor or a statistician or a very good detective.
He is a trader that writes hit pieces.... And this makes him an expert in oncology and trial design how?

Go read the connecting the dots blog on the trial design... You will get a real education there.